{"id":731,"date":"2020-02-02T09:01:20","date_gmt":"2020-02-02T08:01:20","guid":{"rendered":"http:\/\/invivo.partners\/?post_type=portoflio_invivo&#038;p=731"},"modified":"2024-03-05T11:16:38","modified_gmt":"2024-03-05T10:16:38","slug":"sanifit","status":"publish","type":"portoflio_invivo","link":"https:\/\/invivo.partners\/es\/portoflio_invivo\/sanifit\/","title":{"rendered":"Sanifit Therapeutics"},"content":{"rendered":"\r\n<p class=\"wp-block-paragraph\">Sanifit Therapeutics es una empresa <em>spin-off<\/em> de la <strong>Universitat de les Illes Balears<\/strong>. La empresa se centra en tratamientos para los trastornos de calcificaci\u00f3n vascular progresiva. El candidato principal, SNF472, es una nueva mol\u00e9cula peque\u00f1a, inhibidor selectivo y potente de la cristalizaci\u00f3n de la hidroxiapatita (HAP), la v\u00eda com\u00fan que conduce a la calcificaci\u00f3n vascular, en desarrollo cl\u00ednico en pacientes con enfermedad renal en etapa terminal (ESKD), <strong>calcifilaxis<\/strong> y enfermedad arterial perif\u00e9rica (<strong>PAD<\/strong>).<\/p>\r\n\r\n\r\n\r\n<ul class=\"wp-block-list\">\r\n<li>CEO y cofundador: Joan Perell\u00f3<\/li>\r\n<li>Ubicaci\u00f3n: Palma de Mallorca (Islas Baleares) y San Diego (EEUU)<\/li>\r\n<li>P\u00e1gina web: <strong><a href=\"http:\/\/www.sanifit.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">sanifit.com<\/a><\/strong><\/li>\r\n<li>Adquisici\u00f3n: Vifor Pharma<\/li>\r\n<\/ul>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\r\n","protected":false},"featured_media":0,"template":"","tipo_portfolio":[506],"class_list":["post-731","portoflio_invivo","type-portoflio_invivo","status-publish","hentry","tipo_portfolio-healthequity"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sanifit Therapeutics - Invivo Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/es\/portoflio_invivo\/sanifit\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanifit Therapeutics - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"Sanifit Therapeutics es una empresa spin-off de la Universitat de les Illes Balears. La empresa se centra en tratamientos para los trastornos de calcificaci\u00f3n vascular progresiva. El candidato principal, SNF472, es una nueva mol\u00e9cula peque\u00f1a, inhibidor selectivo y potente de la cristalizaci\u00f3n de la hidroxiapatita (HAP), la v\u00eda com\u00fan que conduce a la calcificaci\u00f3n vascular,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/es\/portoflio_invivo\/sanifit\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-05T10:16:38+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/sanifit\/\",\"url\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/sanifit\/\",\"name\":\"Sanifit Therapeutics - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2020-02-02T08:01:20+00:00\",\"dateModified\":\"2024-03-05T10:16:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/sanifit\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/es\/portoflio_invivo\/sanifit\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/sanifit\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanifit Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sanifit Therapeutics - Invivo Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/es\/portoflio_invivo\/sanifit\/","og_locale":"es_ES","og_type":"article","og_title":"Sanifit Therapeutics - Invivo Partners","og_description":"Sanifit Therapeutics es una empresa spin-off de la Universitat de les Illes Balears. La empresa se centra en tratamientos para los trastornos de calcificaci\u00f3n vascular progresiva. El candidato principal, SNF472, es una nueva mol\u00e9cula peque\u00f1a, inhibidor selectivo y potente de la cristalizaci\u00f3n de la hidroxiapatita (HAP), la v\u00eda com\u00fan que conduce a la calcificaci\u00f3n vascular,","og_url":"https:\/\/invivo.partners\/es\/portoflio_invivo\/sanifit\/","og_site_name":"Invivo Partners","article_modified_time":"2024-03-05T10:16:38+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/sanifit\/","url":"https:\/\/invivo.partners\/es\/portoflio_invivo\/sanifit\/","name":"Sanifit Therapeutics - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2020-02-02T08:01:20+00:00","dateModified":"2024-03-05T10:16:38+00:00","breadcrumb":{"@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/sanifit\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/es\/portoflio_invivo\/sanifit\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/sanifit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/es\/"},{"@type":"ListItem","position":2,"name":"Sanifit Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/portoflio_invivo\/731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/portoflio_invivo"}],"about":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/types\/portoflio_invivo"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/media?parent=731"}],"wp:term":[{"taxonomy":"tipo_portfolio","embeddable":true,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/tipo_portfolio?post=731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}